Springfeld C, Hackert T, Jäger D, Büchler M W, Neoptolemos J P
Abteilung Medizinische Onkologie, Nationales Zentrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland.
Klinik für Allgemein‑, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Chirurg. 2020 Aug;91(8):636-641. doi: 10.1007/s00104-020-01169-9.
Resection is the only curative treatment option for pancreatic cancer patients. Adjuvant chemotherapy can improve disease-free survival and overall survival after resection. Furthermore, neoadjuvant treatment protocols are currently being investigated in a large number of studies.
Summary of the current evidence for adjuvant and neoadjuvant treatment.
Review of the current scientific literature and guidelines.
After resection for pancreatic cancer patients should receive intensive chemotherapy with mFOLFIRINOX, gemcitabine plus capecitabine or gemcitabine/5-fluorouracil (5-FU) monotherapy. Neoadjuvant treatment concepts are promising but have to be further evaluated in prospective studies.
手术切除是胰腺癌患者唯一的治愈性治疗选择。辅助化疗可提高切除术后的无病生存期和总生存期。此外，目前大量研究正在探索新辅助治疗方案。
总结辅助治疗和新辅助治疗的现有证据。
回顾当前的科学文献和指南。
胰腺癌患者术后应接受mFOLFIRINOX、吉西他滨联合卡培他滨或吉西他滨/5-氟尿嘧啶（5-FU）单药强化化疗。新辅助治疗概念很有前景，但必须在前瞻性研究中进一步评估。
